Zydus Life surges as its JV inks pact to set up pharmaceutical manufacturing facility in Sri Lanka
Mumbai, October 15 (Udaipur Kiran): Zydus Lifesciences is currently trading at Rs. 1143.10, up by 19.10 points or 1.70% from its previous closing of Rs. 1124.00 on the BSE.
The scrip opened at Rs. 1124.00 and has touched a high and low of Rs. 1146.25 and Rs. 1116.70 respectively. So far 48436 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 1232.00 on 29-Sep-2026 and a 52 week low of Rs. 835.85 on 02-Apr-2026.
Last one week high and low of the scrip stood at Rs. 1,150.90 and Rs. 1105.00 respectively. The current market cap of the company is Rs. 112543.37 crore.
The promoters holding in the company stood at 75.01%, while Institutions and Non-Institutions held 18.33% and 6.66% respectively.
Zydus Lifesciences’ joint venture (JV) — Zydus Sunshine Lifesciences has inked an agreement with the Board of Investment of Sri Lanka to establish a pharmaceutical manufacturing facility in the BOI zone in Horana, Sri Lanka. The Zydus Sunshine Lifesciences is a joint venture between the company and Sunshine Healthcare, part of Sunshine Holdings PLC.
The project envisages a phased investment of over $20 million. The facility will be developed on a site of nearly four acres, with commercial operations expected to commence in 2028, subject to project timelines and relevant regulatory approvals.
In its first phase, the facility will manufacture oral solid dosage forms for the Sri Lankan market. The investment supports the company’s international presence and commitment to expanding access to quality medicines. Local manufacturing is expected to strengthen medicine supply chain resilience and support the availability of essential medicines in Sri Lanka.
Zydus Lifesciences is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating, manufacturing, marketing and selling of finished dosage human formulations, active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
